Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2016

Open Access 01-12-2015 | Research

Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis?

Authors: Hervé Quintard, Sébastien Leduc, Patricia Ferrari, Isabelle Petit, Carole Ichai

Published in: Critical Care | Issue 1/2016

Login to get access

Abstract

Background

Protein S100β (PS100 β) and neuron specific enolase (NSE) have been described as biological markers of neuronal damage. The purpose of our study was to assess the prognosis thresholds of these biomarkers in subarachnoid aneurysmal hemorrhage (SAH).

Methods

Forty eight patients admitted following SAH were treated by endovascular coiling. Initial neurologic severity was assessed using the World Federation Neurologic Surgeons (WFNS), Fisher grades, initial Glasgow coma scale (GCS) and SAPS II. PS100β and NSE plasma concentration were measured daily within the first week. The primary endpoint of the study was the 6-month Glasgow Outcome Score (GOS) dichotomized as poor (GOS 1–3) or good (GOS 4–5).

Results

A poor outcome at 6-months was associated with significant higher levels of S100β value from day 1 to day 7, whereas NSE values were significantly higher from day 5 to day 7. Best threshold value, for prognosis, was obtained at day 5 for PS100β >0.13 μg/L (specificity 0.95 95 % confidence interval (CI) 0.74–1; sensitivity 0.83 95 % CI 0.65–0.93) and day 7 for NSE >14.5 μg/L (specificity 0.90 95 % CI 0.67–0.98); sensitivity (0.69 95 % CI 0.51–0.83)). After multivariate logistic analysis, only PS100β at day 5 and SAPS II enabled to predict neurological outcome at 6 months (p <0.05).

Conclusion

PS100β >0.13 μg/L at day 5 is an independent predicting factor of poor neurological outcome at 6 months following SAH. This result could support the use of this biomarker at the acute phase of SAH to help physician determine the prognosis.
Appendix
Available only for authorised users
Literature
1.
Connolly Jr ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012;43(6):1711–37.CrossRefPubMed
2.
Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry. 1988;51(11):1457.PubMedCentralCrossRefPubMed
3.
Soehle M, Chatfield DA, Czosnyka M, Kirkpatrick PJ. Predictive value of initial clinical status, intracranial pressure and transcranial Doppler pulsatility after subarachnoid haemorrhage. Acta Neurochir. 2007;149(6):575–83.CrossRefPubMed
4.
Lindvall P, Runnerstam M, Birgander R, Koskinen LO. The Fisher grading correlated to outcome in patients with subarachnoid haemorrhage. Br J Neurosurg. 2009;23(2):188–92.CrossRefPubMed
5.
Usui A, Kato K, Murase M, Hotta T, Tanaka M, Takeuchi E, et al. Neural tissue-related proteins (NSE, G0 alpha, 28-kDa calbindin-D, S100b and CK-BB) in serum and cerebrospinal fluid after cardiac arrest. J Neurol Sci. 1994;123(1–2):134–9.CrossRefPubMed
6.
Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, et al. Serum neurone-specific enolase as an indicator of stroke volume. Eur J Clin Invest. 1996;26(4):298–303.CrossRefPubMed
7.
Hårdemark HG, Ericsson N, Kotwica Z, Rundström G, Mendel-Hartvig I, Olsson Y, et al. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg. 1989;71(5 Pt 1):727–31.CrossRefPubMed
8.
Martens P, Raabe A, Johnsson P. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke. 1998;29(11):2363–6.CrossRefPubMed
9.
Weiss N, Sanchez-Peña P, Roche S, Beaudeux JL, Colonne C, Coriat P, et al. Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology. 2006;104(4):658–66.CrossRefPubMed
10.
Oertel M, Schumacher U, McArthur DL, Kästner S, Böker DK. S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci. 2006;13(8):834–40.CrossRefPubMed
11.
Moritz S, Warnat J, Bele S, Graf BM, Woertgen C. The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2010;22(1):21–31.CrossRefPubMed
12.
Vos PE, van Gils M, Beems T, Zimmerman C, Verbeek MM. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol. 2006;13(6):632–8.CrossRefPubMed
13.
Jung CS, Lange B, Zimmermann M, Seifert V. CSF and Serum Biomarkers Focusing on Cerebral Vasospasm and Ischemia after Subarachnoid Hemorrhage. Stroke Res Treat. 2013;560305.
14.
Stranjalis G, Korfias S, Psachoulia C, Kouyialis A, Sakas DE, Mendelow AD. The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir. 2007;149(3):231–7. discussion 237–238.CrossRefPubMed
15.
Pereira AR, Sanchez-Peña P, Biondi A, Sourour N, Boch AL, Colonne C, et al. Predictors of 1-year outcome after coiling for poor-grade subarachnoid aneurysmal hemorrhage. Neurocrit Care. 2007;7(1):18–26.CrossRefPubMed
16.
Saveland H, Brandt L. Which are the major determinants for outcome in aneurysmal subarachnoid hemorrhage? A prospective total management study from a strictly unselected series. Acta Neurol Scand. 1994;90(4):245–50.CrossRefPubMed
17.
Timsit JF, Fosse JP, Troché G, De Lassence A, Alberti C, Garrouste-Orgeas M, et al. Accuracy of a composite score using daily SAPS II and LOD scores for predicting hospital mortality in ICU patients hospitalized for more than 72 h. Intensive Care Med. 2001;27(6):1012–21.CrossRefPubMed
18.
Turck N, Vutskits L, Sanchez-Pena P, Robin X, Hainard A, Gex-Fabry M, et al. A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhage. Intensive Care Med. 2010;36(1):107–15.CrossRefPubMed
19.
Ariyoshi Y, Kato K, Ishiguro Y, Ota K, Sato T, Suchi T. Neuron-specific enolase as a new tumor marker. Gan To Kagaku Ryoho. 1983;10(8):1744–53.PubMed
20.
Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg. 1999;13(1):56–9.CrossRefPubMed
21.
Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir. 1997;139(12):1161–4. discussion 1165.CrossRefPubMed
22.
Ingebrigtsen T, Waterloo K, Jacobsen EA, Langbakk B, Romner B. Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery. 1999;45(3):468–75. discussion 475–466.CrossRefPubMed
23.
Büttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke. 1997;28(10):1961–5.CrossRefPubMed
24.
Korfias S, Stranjalis G, Papadimitriou A, Psachoulia C, Daskalakis G, Antsaklis A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem. 2006;13(30):3719–31.CrossRefPubMed
25.
Wiesmann M, Missler U, Hagenström H, Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1997;139(12):1155–60.CrossRefPubMed
26.
Persson L, Hårdemark HG, Gustafsson J, Rundström G, Mendel-Hartvig I, Esscher T, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987;18(5):911–8.CrossRefPubMed
27.
Kumar PV, Vannemreddy P, Kumar D, Nanda A, Reddy P. Cardiac troponin I levels are a marker of myocardial dysfunction in subarachnoid hemorrhage and predicts poor neurologic outcome. J La State Med Soc. 2011;163(5):257–60.PubMed
28.
Gupte M, John S, Prabhakaran S, Lee VH. Troponin elevation in subarachnoid hemorrhage does not impact in-hospital mortality. Neurocrit Care. 2013;18(3):368–73.CrossRefPubMed
29.
Nylén K, Csajbok LZ, Ost M, Rashid A, Blennow K, Nellgård B, et al. Serum glial fibrillary acidic protein is related to focal brain injury and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(5):1489–94.CrossRefPubMed
Metadata
Title
Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis?
Authors
Hervé Quintard
Sébastien Leduc
Patricia Ferrari
Isabelle Petit
Carole Ichai
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2016
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-016-1200-1

Other articles of this Issue 1/2016

Critical Care 1/2016 Go to the issue

Research

Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study

Research

The involvement of regulatory non-coding RNAs in sepsis: a systematic review

Letter

Benefit of prokinetics during enteral nutrition: still searching for a piece of evidence

Review

Advances in antibiotic therapy in the critically ill

Research

Use of intra-osseous access in adults: a systematic review

Review

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal